Image

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting
20 years of age
Both
Phase 3

Powered by AI

Overview

To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC.

Eligibility

Inclusion Criteria:

  • Have at entry, confirmed by a pathology report:
    1. Carcinoma in situ (CIS) only
    2. Ta/T1 high-grade disease with concomitant CIS or
    3. Ta/T1 high-grade disease without concomitant CIS
  • Subjects who did not respond to BCG treatment and have a persistent high-grade

    recurrence within 12 months after BCG was initiated, and those who despite an initial complete response to BCG, relapse with CIS within 12 months of their last intravesical treatment with BCG or relapse with high-grade Ta/T1 NMIBC within 6 months of their last intravesical treatment with BCG.

  • Life expectancy >2 years, in the opinion of the investigator
  • Eastern Cooperative Oncology Group (ECOG) status 2 or less
  • Absence of concomitant upper tract urothelial carcinoma or urothelial carcinoma within the prostatic urethra
  • Subjects with prostate cancer on active surveillance at low risk for progression, defined as prostate-specific antigen (PSA) <10 ng/dL

Exclusion Criteria:

  • Current or previous evidence of muscle invasive (muscularis propria) or metastatic disease presented at the screening visit.
  • Current systemic therapy for bladder cancer
  • Current or prior investigational treatment for BCG unresponsive NMIBC or any other investigational drug within 1 month prior to screening
  • Current or prior pelvic external beam radiotherapy within 5 years of entry
  • Use of other adenovirus vector medications, including COVID-19 vaccines, within 2 weeks before and after instillation
  • History of malignancy of other organ system within past 5 years, except treated basal cell carcinoma or squamous cell carcinoma of the skin and ≤pT2 upper tract urothelial carcinoma at least 24 months after nephroureterectomy.
  • Subjects who cannot hold instillation for 1 hour
  • Subjects who cannot tolerate intravesical dosing or intravesical surgical manipulation
  • Intravesical therapy within 8 weeks prior to beginning trial treatment, with the exception of:
    • Cytotoxic agents when administered as a single instillation immediately following a TURBT procedure
    • Previous intravesical BCG therapy
  • Systemic immunosuppressive therapy within 3 months prior to screening

Study details

Bladder Cancer

NCT05704244

Ferring Pharmaceuticals

15 June 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.